Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Does Similarity Breed Contempt? A Review of the Use of Biosimilars in Inflammatory Bowel Disease
Shubha Bhat, Jimmy K. Limdi, Raymond K. Cross, et al.
Digestive Diseases and Sciences (2021) Vol. 66, Iss. 8, pp. 2513-2532
Closed Access | Times Cited: 14

Showing 14 citing articles:

Biosimilars versus biological therapy in inflammatory bowel disease: challenges and targeting strategies using drug delivery systems
Ahmed Aljabri, Ghareb M. Soliman, Yasmin N. Ramadan, et al.
Clinical and Experimental Medicine (2025) Vol. 25, Iss. 1
Open Access | Times Cited: 1
A review of the therapeutic management of Crohn’s disease
Aditi Kumar, Alexander J. Cole, Jonathan Segal, et al.
Therapeutic Advances in Gastroenterology (2022) Vol. 15
Open Access | Times Cited: 33
Biosimilars in IBD: What Every Clinician Needs to Know
Anthony Angyal, Shubha Bhat
Current Gastroenterology Reports (2024) Vol. 26, Iss. 3, pp. 77-85
Closed Access | Times Cited: 8
Inflammatory Bowel Disease: From Conventional Immunosuppression to Biologic Therapy
Aleksandra Sokić-Milutinović, Tomica Milosavljević
Digestive Diseases (2023) Vol. 42, Iss. 4, pp. 325-335
Open Access | Times Cited: 9
Systematic Literature Review of Real-World Evidence on Dose Escalation and Treatment Switching in Ulcerative Colitis
Harpreet Singh, Liam Wilson, T. Tencer, et al.
ClinicoEconomics and Outcomes Research (2023) Vol. Volume 15, pp. 125-138
Open Access | Times Cited: 7
Patient-Reported Outcomes in Rheumatoid Arthritis: A Key Consideration for Evaluating Biosimilar Uptake?
Gabriel Horta‐Baas
Patient Related Outcome Measures (2022) Vol. Volume 13, pp. 79-95
Open Access | Times Cited: 8
Adalimumab-Adbm: The First Interchangeable Biosimilar for the Treatment of Inflammatory Diseases
Shubha Bhat, Maitri Patel, Kristine Duly, et al.
Annals of Pharmacotherapy (2022) Vol. 56, Iss. 12, pp. 1356-1364
Closed Access | Times Cited: 7
Biosimilars in Pediatric IBD: Updated Considerations for Disease Management
Valeria Dipasquale, U Cucinotta, Claudio Romano
Biologics (2022) Vol. Volume 16, pp. 57-66
Open Access | Times Cited: 6
Patient and Caregivers’ Perspectives on Biosimilar Use in Pediatric Inflammatory Bowel Disease
Lina Yossef, Molly Wright, Jason Benedict, et al.
Journal of Pediatric Gastroenterology and Nutrition (2022) Vol. 75, Iss. 1, pp. 59-63
Closed Access | Times Cited: 3
Attitudes, perceptions and barriers in implementing therapeutic drug monitoring for anti-TNFs in inflammatory bowel disease: a survey from the Middle East
Gaurav Nigam, Kelly Chatten, Ala I. Sharara, et al.
Therapeutic Advances in Gastroenterology (2024) Vol. 17
Open Access
Shot heard around the world? Subcutaneous Infliximab (CT-P13) as Maintenance Therapy for Inflammatory Bowel Disease
Catalina Mulanax, Fernando Velayos
Gastroenterology (2024) Vol. 167, Iss. 5, pp. 841-842
Closed Access
Real-world experience with biosimilar infliximab-adba and infliximab-dyyb among infliximab-naïve patients with inflammatory bowel disease in the Veterans Health Administration
Shardool Patel, Jessica A. Walsh, Derek Pinnell, et al.
Medicine (2024) Vol. 103, Iss. 37, pp. e39476-e39476
Open Access
Patient Reported Outcomes for SB5, an adalimumab biosIMILAR, in patients with rheumatoid arthritis and ankylosing spondylitis (PRO-SIMILAR): Study protocol for a phase IV, single-arm, open-label trial
Jisoo Lee, Sung-Soo Kim, Sang Il Lee, et al.
Medicine Case Reports and Study Protocols (2024) Vol. 5, Iss. 12, pp. e00341-e00341
Closed Access
Adalimumab originator versus adalimumab biosimilars in inflammatory bowel disease in Australia
Emilia Anderson, Karen Waller, Aravind Gokul Tamilarasan, et al.
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 8, pp. 819-825
Closed Access
Page 1

Scroll to top